SarcoMed USA was established in 2017 to explore the potential impact of a new DNase 1 compound (SM001) on the persistent pulmonary inflammation observed in patients with Pulmonary Sarcoidosis. Sarcoidosis is a systemic granulomatous disease characterized by a T-helper-1 response, leading to the accumulation of CD4+ lymphocytes and activated macrophages in the lungs and affected organs, resulting in the formation of characteristic granulomas. The lungs are affected in over 90% of sarcoidosis patients, leading to abnormal pulmonary function in many individuals. Sarcoidosis affects approximately 200,000 individuals in the United States.